KBB-Forum 2020 , Cilt 19, Sayı 1

EVALUATION OF HEARING LOSS IN PATIENTS WITH OSAS AND THE RELATIONSHIP BETWEEN S100B AND NSE

Cengiz ARLI 1, MD; Elif Tugba SARAC 2, MD; Oguzhan OZCAN 4, MD; Cenk BABAYIGIT 3, MD; Nursel DIKMEN 3, MD; Sibel DOGRU 5, MD; Emine Esra OKUYUCU 6, MD;
1Hatay Mustafa Kemal University, Department of Ear, Nose and Throat, Hatay, Turkey
2Hatay Mustafa Kemal University, Audiology Department, Hatay, Turkey
3Hatay Mustafa Kemal University, Department of Thoracic Medicine, Hatay, Turkey
4Hatay Mustafa Kemal University, Department of Biochemistry, Hatay, Turkey
5Osmaniye Sevgi Hospital, Thoracic Medicine, Osmaniye, Turkey
6Hatay Mustafa Kemal University, Department of Neurology, Hatay, Turkey Objective: The aim of the current study was to determine the relationship between serum S100B levels, NSE levels and hearing function in patients with OSAS.

Material and Methods: Thirty-five subjects and 30 controls were included in the study. The study group included 35 patients with moderate and severe apnoea (AHI > 15) who were diagnosed by polysomnography (PSG). Control subjects were selected with ESS (Epworth Sleepiness Scale). Serum S100B and NSE levels in the study and control groups were analyzed by ELISA (enzyme-linked immunosorbent assay) and high-frequency audiometry was done for all subjects.

Results: Mean S100B levels and NSE levels of the OSAS group were significantly higher than that of the controls (p = 0.039; p = 0.002, respectively). The hearing thresholds between 125-1,000 Hz and between 4,000-12,000 Hz in the study group were found to be significantly higher than the control group.

Conclusion: We suggest that hearing function should be evaluated in OSAS patients and a professional consultation should be sought for OSAS treatment. In addition, serum S100B and NSE measurements may be valued as biochemical indicators in determining hearing loss risk caused by OSAS. Keywords : OSAS; S100B; NSE; Hearing loss